Dr. Shia’s research interests are centralized on three major areas: (1) development of antiviral and antibiotic agents against local and/or global infectious diseases (e.g., EV-71 and MRSA); (2) development of agents for treating metabolic disorders (e.g., T2D) based on novel molecular targets (e.g., peripheral CB1 receptors); (3) development of CXCR4-targeting stem cell mobilizers for tissue repair (e.g., AKI), ischaemic diseases (e.g., IS, HCC, mTBI and MI) as well as peripheral blood stem cell transplantation (PBSCT). In parallel, his laboratories also maintain a high momentum on developing new synthetic methodologies and total synthesis of natural products with structural complexity and/or diverse bioactivities.